“
“BACKGROUND: The understanding of chronic rejection (transplant vascular sclerosis, or TVS) mechanisms is a major goal of transplantation. In this study we tested a cardiac transplant model for TVS development in connection with emerging T-regulatory cells (T-regs). We used 40-mer peptides derived from the donor MHC Class I find more alpha 1 helix of the alpha 1-domain to make recipients tolerant.
METHODS: ACI recipients were transplanted with either RTI.A (WF), RTI.A(1) (LEW), RTI.A(c) (PVG), or RTI.A(b) (BUF) cardiac grafts. The grafts were analyzed 120 days later for TVS and development of T-regs.
RESULTS: Donor MHC peptides were injected through the portal vein (0.1 mg) into ACI
recipients of WF hearts in addition to sub-therapeutic cyclosporine (CsA, 10 mg/kg for 3 days post-operatively). Peptide treatment specifically prolonged graft survival for >100 days (n = 31). ACI recipients of WF or LEW hearts treated with PVG peptides promptly rejected
the transplanted grafts (15 +/- 4 and 20 +/- I days, respectively). Presence of T-regs in tolerant recipients was confirmed by the adoptive transfer of T cells into a new cohort of syngeneic recipients (mean survival time [MST] >100 days, n = 3). CD4(+) and FoxP3(+) cells were detected in 70% of the chronically rejected Quisinostat cost grafts vs 38% (CD4) and 22% (FoxP3) in the well-preserved transplants. IgG and IgM deposits were found in only half of surviving cardiac grafts with a high level of TVS. Blood vessels in grafts with attenuated TVS were 80% IgG and IgM positive. Interleukin (IL)-4 and IL-2 were markedly down-regulated in the hearts with high TVS compared with well-preserved grafts.
Long-term-surviving hearts demonstrated LY3023414 inhibitor increased IL-10 expression. Interferon-gamma (IFN-gamma) was more evident in the grafts with a high TVS.
CONCLUSIONS: Donor MHC Class I peptides can specifically prolong transplant survival and generate T-regs. The level of intragraft T-regs correlates with severity of TVS and IL-2/IL-4 down-regulation. J Heart Lung Transplant 2010;29:335-41 (C) 2010 International Society for Heart and Lung Transplantation. All rights reserved.”
“Background: Women with cervical cancer now have relatively good 5-year survival rates. Better survival rates have driven the paradigm in cancer care from a medical illness model to a wellness model, which is concerned with the quality of women’s lives as well as the length of survival. Thus, the assessment of quality of life among cervical cancer survivors is increasingly paramount for healthcare professionals. The purposes of this review were to describe existing validated quality of life instruments used in cervical cancer survivors, and to reveal the implications of quality of life measurement for Chinese cervical cancer survivors.